RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+23.76%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$4.34B
AUM Growth
+$4.34B
(+12%)
Cap. Flow
-$78.5M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
111
New
4
Increased
17
Reduced
21
Closed
25
Top Buys
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$65M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$40.9M |
| 3 |
PTC Therapeutics
PTCT
|
$28.9M |
| 4 |
Immunocore
IMCR
|
$21.4M |
| 5 |
Masimo
MASI
|
$12.6M |
Top Sells
| 1 |
Quanterix
QTRX
|
$29.5M |
| 2 |
Tandem Diabetes Care
TNDM
|
$28.7M |
| 3 |
Veru
VERU
|
$25.1M |
| 4 |
Globus Medical
GMED
|
$22.3M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$20.8M |
Sector Composition
| 1 | Healthcare | 99.21% |
| 2 | Financials | 0.67% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $337M | 7.77% | 1,683,362 | – | – |
|
|
2
PTC Therapeutics
PTCT
$3.92B
| $282M | 6.5% | 5,620,580 +575,273 | +11% | +$28.9M |
|
3
Rocket Pharmaceuticals
RCKT
$354M
| $252M | 5.81% | 15,802,802 | – | – |
|
4
Thermo Fisher Scientific
TMO
$186B
| $221M | 5.09% | 435,500 | – | – |
|
|
5
Immunocore
IMCR
$1.62B
| $209M | 4.82% | 4,451,483 +455,329 | +11% | +$21.4M |
|
|
6
Masimo
MASI
$7.59B
| $203M | 4.69% | 1,439,993 +89,000 | +7% | +$12.6M |
|
|
RXDX
7
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $188M | 4.34% | 3,189,605 | – | – |
|
8
argenx
ARGX
$43.6B
| $165M | 3.8% | 467,195 +24,560 | +6% | +$8.67M |
|
9
Penumbra
PEN
$10.6B
| $132M | 3.05% | 698,371 | – | – |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $131M | 3.03% | 1,882,663 | – | – |
|
11
Establishment Labs
ESTA
$1.2B
| $129M | 2.98% | 2,369,138 | – | – |
|
12
Cytokinetics
CYTK
$4.23B
| $125M | 2.88% | 2,574,198 +13,016 | +0.5% | +$631K |
|
13
Illumina
ILMN
$15.8B
| $108M | 2.48% | 564,375 | – | – |
|
14
Relmada Therapeutics
RLMD
$37.2M
| $97.9M | 2.26% | 2,644,475 +6,894 | +0.3% | +$255K |
|
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $97.7M | 2.25% | 2,359,996 +986,712 | +72% | +$40.9M |
|
16
Natera
NTRA
$23.1B
| $96.8M | 2.23% | 2,209,283 +87,000 | +4% | +$3.81M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $86.7M | 2% | 3,084,215 | – | – |
|
18
Avidity Biosciences
RNA
$5.99B
| $84.4M | 1.95% | 5,170,784 +375,784 | +8% | +$6.14M |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $84M | 1.94% | 1,882,164 +263,345 | +16% | +$11.8M |
|
|
CUTR
20
DELISTED
Cutera, Inc.
CUTR
| $80.7M | 1.86% | 1,770,400 | – | – |
|
21
Vericel Corp
VCEL
$1.83B
| $71.9M | 1.66% | 3,099,904 -423,000 | -12% | -$9.81M |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $65M | 1.5% | +3,625,000 | New | +$65M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $62.3M | 1.44% | 884,974 -294,991 | -25% | -$20.8M |
|
24
Adicet Bio
ACET
$59.9M
| $60.3M | 1.39% | 4,241,472 +290,191 | +7% | +$4.13M |
|
25
Acadia Pharmaceuticals
ACAD
$4.38B
| $60.1M | 1.38% | 3,670,938 -553,171 | -13% | -$9.05M |
|